INZY

Inozyme Pharma, Inc.

4.41 USD
+0.01 (+0.23%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Inozyme Pharma, Inc. stock is down -6.77% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 June’s closed higher than May. 100% of analysts rate it a buy.

About Inozyme Pharma, Inc.

Inozyme Pharma, Inc. engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. Lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.